TTF-1 monoclonal comparison

scoring(0: no expression or faint expression of <5% of the tumor nuclei, 1: when faint expression of >=5% of the tumor nuclei, 2: when bright expression of >=5% of the tumor nuclei. 1 and 2 were considered as positive staining.)

SPT24 (from Novocastra etc)

8G7G3/1 (from Dako etc)

BGX-397A

Pulmonary small cell carcinoma

7/84

7/84

Pulmonary atypical carcinoid

5/54

2/54

Pulmonary typical carcinoid

5/114

1/114

Primary pulmonary adenocarcinoma

72/861, 12/174

56/86(all positive cases were also positive with SPT24. 13 cases with a score of "1" scored "2" using SPT24)1, 11/174

Pulmonary large cell carcinoma

6/124

5/124

Pulmonary squamous cell carcinoma

2/144

1/144

Gastric adenocarcinoma

1/12(in three additional cases, < 10% of neoplastic cells stained)4

0/12(in one case, < 10% of neoplastic cells stained, a cytoplasmic reaction was occasionally seen in the neoplastic cells)4

Primary colorectal carcinoma

4/90(using tissue microarrays: the positive cases showed staining of 20-40~% of nuclei, often associated with cytoplasmic staining.)1, 3/6(three cases showed focal positivity)2, 1/17(in one additional case, <10% of neoplastic cells stained)4

0/901, 0/62, 0/174

Lung metastases from primary colorectal adenocarcinoma

4/41(Staining was seen in 10-40% of the nuclei of the positive cases. In two cases, nuclear staining was associated with cytoplasmic staining. All had documented colorectal primaries, with lung metastases showing the typical morphology of colorectal metastases and all CK7-/CK20+. In all three cases where suitable material was available, extra-pulmonary tumour was also TTF-1 positive.)1

0/41(both primaries and lung metastases were negative. One case showed very faint nuclear graying, below the threshold for positivity.)1

Nodal metastasis from colorectal carcinoma

1(case report: also positive in primary tumour: staining was stronger than for 8G7G3/1)3

1(case report: also positive in primary tumour)3

Liver metastasis from colorectal carcinoma

1(case report: staining was stronger than for 8G7G3/1)3

1(case report)3

Lung metastases from renal carcinoma

0/61

0/61

Intestinal carcinoid

0/284

0/28(a cytoplasmic reaction was occasionally seen in the neoplastic cells)4

Pancreas adenocarcinoma

0/5(in one case, < 10% of neoplastic cells stained)4

0/54

Breast adenocarcinoma

0/144, 0/2(metastatic to lung)1

0/144, 0/2(metastatic to lung)1

Prostatic adenocarcinoma

0/84

0/8(a cytoplasmic reaction was occasionally seen in the neoplastic cells)4

Ovarian serous carcinoma

1/64, 1/20(TMA; positivity in less than 25% of nuclei in one case^b)5, 6/36(surgical specimens ; positivity in >50% of nuclei in 2 cases, 3% to 25% of nuclei in one case, < 3% in 3 cases^b)5

1/6(a cytoplasmic reaction was occasionally seen in the neoplastic cells)4, 0/20(TMA)5, 2/36(surgical specimens; positivity in >50% of nuclei in two case)5

1/20(TMA; positivity in less than 25% of nuclei in one case^b)5

Ovarian clear cell carcinoma

0/54, 2/20(TMA; positivity in 3% to 50% of nuclei in one case, positivity in 26% to 50% of nuclei in one case^b)5, 1/7(surgical specimens; positivity in less than 25% of nuclei in one case^b)5

0/54, 0/20(TMA)5, 1/7(surgical specimens; positivity in less than 3% of nuclei in one case)5

2/20(TMA; positivity in 3% to 50% of nuclei in one case, positivity in 26% to 50% of nuclei in one case^b)5

Ovarian endometrioid carcinoma

0/54, 2/20(TMA; positivity in 26% to 50% of nuclei in one cases^b)5, 0/7(surgical specimens^b)5

0/54, 1/20(TMA; positivity in 26% to 50% of nuclei in one case)5, 0/7(surgical specimens^a)5

2/20(TMA; positivity in 26% to 50% of nuclei in two cases^b)5

Ovarian mucinous carcinoma

1/20(TMA; positivity in 26% to 50% of nuclei in one case^b)5, 1/3(surgical specimens; positivity in < 25% of nuclei in one case^b)5

0/20(TMA^a)5, 0/3(surgical specimens^a)5

1/20(TMA; positivity in 26% to 50% of nuclei in one case^b)5

Ovarian poorly differentiated carcinoma

0/20(TMA^b)5

0/20(TMA^a)5

0/20(TMA^b)5

Ovarian serous cystadenoma

0/4(TMA^b)5

0/4(TMA^a)5

0/4(TMA^b)5

Ovarian mucinous cystadenoma

1/3(TMA; positivity in <25% of nuclei in one case^b)5, 0/2(surgical specimens^b)5

0/3(TMA^a)5, 0/2(surgical specimens^a)5

1/3(TMA; positivity in <25% of nuclei in one case^b)5

Ovarian malignant mixed Mullerian tumour

1/2(surgical specimens; positivity in >50% of nuclei in one case^b)5

0/2(surgical specimens^a)5

Uterine serous carcinoma

4/18(surgical specimens ; positivity in less than 25% of nuclei in four cases^b)5

1/18(surgical specimens; positivity in less than 3% of nuclei in one case^a)5

Uterine endometrioid carcinoma

4/18(surgical specimens; positivity in less than 3% of nuclei in one case, 3 to 25 % of nuclei in two cases, >50% of nuclei in one case^b)5

1/18(surgical specimens ; positivity in >50% of nuclei in one case^a)5

Uterine malignant mixed Mullerian tumour

9/11(surgical specimens; positivity in less than 3% of nuclei in four cases, 3 to 25 % of nuclei in three cases, 25% to 50% of nuclei in two cases^b)5

0/11(surgical specimens^a)5

Glioblastoma multiforme

14/28(<2% of nuclei in 7 cases, 2% to 10% of nuclei in 3 cases, over 30% of nuclei n 4 cases)6

0/286

Gliosarcoma

0/16

0/16

Comparison of TTF-1 clones and staining machines for assorted gynaecological carcinomas selected for their positivity5: